EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Development of membrane‐active peptide therapeutics in oncology

Charles H Chen iD, Bing Zan, Jakob P Ulmschneider, William C Wimley, Timothy K Lu, Martin B Ulmschneider, Liping Zhou

Journal of Peptide Science · 2023

DOI: 10.1002/psc.3482 ↗

At a glance

Übersichtsarbeit in Journal of Peptide Science, 2023. Written by Charles H Chen and 6 co-authors. Institution: Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Massachusetts, Boston, USA. Major MEDLINE topics: Peptides, Proteins. Cited 18 times so far (Crossref); 91 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Membrane‐active peptides play an essential role in many living organisms and their immune systems and counter many infectious diseases. Many have dual or multiple mechanisms and can synergize with other molecules, like peptides, proteins, and small molecules. Although membrane‐active peptides have been intensively studied in the past decades and more than 3500 sequences have been identified, only a few received approvals from the US Food and Drug Administration. In this review, we investigated all the peptide therapeutics that have entered the market or were subjected to preclinical and clinical studies to understand how they succeeded. With technological advancement (e.g., chemical modifications and pharmaceutical formulations) and a better understanding of the mechanism of action and the potential targets, we found at least five membrane‐active peptide drugs that have entered preclinical/clinical phases and show promising results for cancer treatment. We summarized our findings in this review and provided insights into membrane‐active anticancer peptide therapeutics.

Subjects

MeSH terms (MEDLINE)

PeptidesProteinsUnited StatesPharmaceutical PreparationsDrug Delivery SystemsDrug Compounding

Author keywords

membrane-active drugoncologyoncolytic peptidepeptide therapeutics

Substances

PeptidesProteinsPharmaceutical Preparations

Authors and institutions

  • Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Massachusetts, Boston, USA.
  • School of Physics and Astronomy, Institute of Natural Sciences, Shanghai Jiao Tong University, Shanghai, China.
  • Department of Biochemistry and Molecular Biology, Tulane University, LA, New Orleans, USA.
  • Synthetic Biology Group, Research Laboratory of Electronics, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Department of Chemistry, King's College London, London, UK.

ORCID profiles: Charles H Chen

Cite

APA

Chen, C. H., Zan, B., Ulmschneider, J. P., Wimley, W. C., Lu, T. K., Ulmschneider, M. B., & Zhou, L. (2023). Development of membrane‐active peptide therapeutics in oncology. Journal of Peptide Science. https://doi.org/10.1002/psc.3482

Vancouver

Chen CH, Zan B, Ulmschneider JP, Wimley WC, Lu TK, Ulmschneider MB, et al. Development of membrane‐active peptide therapeutics in oncology. Journal of Peptide Science. 2023. doi:10.1002/psc.3482

BibTeX
@article{Chen2023,
  author = {Chen, Charles H and Zan, Bing and Ulmschneider, Jakob P and Wimley, William C and Lu, Timothy K and Ulmschneider, Martin B and Zhou, Liping},
  title = {Development of membrane‐active peptide therapeutics in oncology},
  journal = {Journal of Peptide Science},
  year = {2023},
  doi = {10.1002/psc.3482}
}
Start for free →